The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...
The Food and Drug Administration (FDA) recently approved a new drug from Eli Lilly to treat Alzheimer’s disease. Called ...
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and ...
A team of researchers at UTMB developed a drug that attacks the bad stuff in the brain that causes Alzheimer's. Now, there's ...
Beckman Coulter will use the antibody as part of a p-tau 217 in vitro diagnostic on its DxI 9000 Immunoassay Analyzer to aid in the diagnosis of the disease.
Ozempic and Wegovy have been approved by the FDA ... may be able to treat include dementia, pancreatitis, and polycystic ...
A Connecticut federal judge has dismissed a proposed securities fraud class action against BioXcel Therapeutics Inc.